TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02798146

Intervention type: OTHER
Group type: OTHER
Intervention: blood collection
Description: Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
Study: NCT00537797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDG-PET Scan
Description: Positron emission tomography with 18F-fluorodeoxyglucose
Study: NCT01450631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena™ Incision Management System (PIMS)
Description: PIMS is a non-significant-risk, FDA Class II, medical device commercially available in the USA, Canada and Europe. The prospective, post-marketing clinical study described in this protocol will assess the effectiveness and functional performance of the system. The PIMS unit is a single patient use, battery-powered, disposable unit that can provide continuous -125 mmHg negative pressure over a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care Dressing
Description: The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing. Other therapies include traditional gauze dressings with or without advanced therapies such as hydrocolloids, growth factors, and Negative Pressure Wound Therapy.
Study: NCT01430715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active vido games and outdoor play
Description: Fifteen children, aged 5- to 8- years, attending a nearby preschool, with a normal body mass index (BMI)-for-age percentile between, \> 5th % to \< 85th %.BMI, will participate in unstructured, outdoor play and one AVGs in a randomized order. Activity type, duration and intensity will be measured via accelerometery and direct observation. The energy expenditure (EE) will be calculated from Metabolic Equivalent (MET) values and the percent of time each activity meets MVPA intensity will be calculated. A MET is the energy cost of the activity expressed as kilocalories expended per kilogram of body weight per hour of activity. If EE and intensity in AVG play is similar to EE and intensity in outdoor play, then AVG play could be a great supplement to efforts aimed at increasing PA in children.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active vido games and outdoor play
Description: Fifteen children, aged 5- to 8- years, attending a nearby preschool, with a normal body mass index (BMI)-for-age percentile between, \> 5th % to \< 85th %.BMI, will participate in unstructured, outdoor play and one AVGs in a randomized order. Activity type, duration and intensity will be measured via accelerometery and direct observation. The energy expenditure (EE) will be calculated from Metabolic Equivalent (MET) values and the percent of time each activity meets MVPA intensity will be calculated. A MET is the energy cost of the activity expressed as kilocalories expended per kilogram of body weight per hour of activity. If EE and intensity in AVG play is similar to EE and intensity in outdoor play, then AVG play could be a great supplement to efforts aimed at increasing PA in children.
Study: NCT02333292

Intervention type: DRUG
Intervention: Telaprevir
Description: Initiation of a regimen containing TVR

Intervention type: DRUG
Intervention: Boceprevir
Description: Initiation of a regimen containing BOC

Intervention type: DRUG
Intervention: Sofosbuvir
Description: Initiation of a regimen containing SOF

Intervention type: DRUG
Intervention: Sofosbuvir
Description: Initiation of a regimen containing SOF

Intervention type: DRUG
Intervention: Simeprevir
Description: Initiation of a regimen containing SMV

Intervention type: DRUG
Intervention: Simeprevir
Description: Initiation of a regimen containing SMV

Intervention type: DRUG
Intervention: Daclatasvir
Description: Initiation of a regimen containing DCV

Intervention type: DRUG
Intervention: Ledipasvir
Description: Initiation of a regimen containing LDV

Intervention type: DRUG
Intervention: ritonavir-boosted Paritaprevir/ Ombitasvir
Description: Initiation of a drug combination of PTV/OTV

Intervention type: DRUG
Intervention: Dasabuvir
Description: Initiation of a regimen containing DBV

Intervention type: DRUG
Intervention: Velpatasvir
Description: Initiation of a regimen containing VPV

Intervention type: DRUG
Intervention: Elbasvir
Description: Initiation of a regimen containing EBV

Intervention type: DRUG
Intervention: Grazoprevir
Description: Initiation of a regimen containing GZR
Study: NCT02344862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FYU-981 High dose, (Oral daily dosing for 8 weeks)
Description: Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FYU-981 Middle dose, (Oral daily dosing for 8 weeks)
Description: Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FYU-981 Low dose, (Oral daily dosing for 8 weeks)
Description: Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, (Oral daily dosing for 8 weeks)
Description: Subjects randomized to the placebo arm receive placebo.
Study: NCT01024231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936558 (MDX1106-04)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936558 (MDX1106-04)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936558 (MDX1106-04)
Study: NCT03223987

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Strath® Kräuterhefe Original (liquid)
Description: The food supplement is taken 3 x 1 coffee spoon à 5ml = 15ml per day for three weeks.~Stool analysis at 2nd visit and last visit. Before-after study.
Study: NCT01111552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram oral capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram oral capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram oral capsules.
Study: NCT01024231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936558 (MDX1106-04)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936558 (MDX1106-04)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT01111552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram oral capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole oral capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole oral capsules.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Study drug matching placebo capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Study drug matching placebo capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Study drug matching placebo capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Study drug matching placebo capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Study drug matching placebo capsule.
Study: NCT04167891

Intervention type: DIAGNOSTIC_TEST
Intervention: Calculation of early prognosis score
Description: Early prognosis score will be calculated at intensive care unit admission for each patient based on clinical and biological values as required
Study: NCT02097225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02026908

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostate Artery Embolization
Description: Procedure completed in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Embosphere microspheres to slow/block blood flow to the prostate.
Study: NCT01695980

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ETT with non modified retractor
Description: adenotonsillectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LMA with modified retractor
Description: LMA with modified retractor
Study: NCT00633139

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human Arylsulfatase A (rhASA)
Description: intravenous infusion, every other week for 26 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human Arylsulfatase A (rhASA)
Description: intravenous infusion, every other week for 26 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human Arylsulfatase A (rhASA)
Description: intravenous infusion, every other week for 26 weeks
Study: NCT00758927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 acid 4 grams per day
Description: OMACOR 4 grams per day is administered simultaneously with exercise and diet therapy
Study: NCT02097225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV
Study: NCT00758927

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo will be administered simultaneously with exercise and diet therapy in same intensity with the experimental arm
Study: NCT01815710

Intervention type: OTHER
Intervention: Pediatric Asthma Clinical Pathway
Description: Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with asthma. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.

Intervention type: OTHER
Intervention: Vomiting & Diarrhea Pathway
Description: Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with vomiting and diarrhea. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
Study: NCT02122861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID-LV305
Description: pembrolizumab
Study: NCT02097225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT04619628

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-VAC
Description: intranasal, live attenuated vaccine against SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-VAC
Description: intranasal, live attenuated vaccine against SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-VAC
Description: intranasal, live attenuated vaccine against SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-VAC
Description: intranasal, live attenuated vaccine against SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-VAC
Description: intranasal, live attenuated vaccine against SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-VAC
Description: intranasal, live attenuated vaccine against SARS-CoV-2

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline
Study: NCT01166698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9819
Description: Inhaled single doses of suspension via SPIRA nebuliser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9819
Description: Inhaled multiple doses of suspension via SPIRA nebuliser, once daily for 10 (maximum 14) days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B)
Study: NCT05259098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil Sublingual Tablet System
Description: Sufentanil Sublingual Tablet System is a sublingual opioid patient controlled analgesia system. It was used for postoperative analgesia after surgery associated with moderate to severe pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Patient-Controlled Analgesia with morfine
Description: Intravenous Patient-Controlled Analgesia with morfine. It was used for postoperative analgesia after surgery associated with moderate to severe pain.
Study: NCT02321514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tendyne Mitral Valve System
Description: Patients will undergo transcatheter mitral valve replacement using Tendyne Mitral Valve system
Study: NCT01024231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT04224740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive pembrolizumab at the dose of 200mg IV Q3W with maximum duration of 2 years (34 cycles-counting the part combined with chemotherapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care therapy
Description: Ciplastin 70mg/m² IV D1(or carboplatin AUC 5) plus 5-Fluouracil 1000mg/m²/day IV( continuous infusion on Days 1-4) Q3W for 6 cycles
Study: NCT01029288

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Medication Choice Decision Aid
Description: Diabetes Medication Choice cards

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Statin Choice Decision Aid
Description: Statin Choice Cards

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care for lipid therapy medication
Description: Clinicians will follow their clinic's usual care practice for lipid therapy medication (statin) discussions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care for antihyperglycemic medication
Description: Clinicians will follow their clinic's usual care practice for antihyperglycemic medication discussions.
Study: NCT03417284

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo HSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo HSCT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim-sndz
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim-sndz
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan Hydrochloride
Description: Given IV
Study: NCT04617613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole, Amoxicillin, Metronidazole and Clarithromycin
Description: The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole, Amoxicillin and Clarithromycin
Description: The first group (standard triple therapy group) received omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg. The second group (quadruple therapy group) received omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg. Patients in both groups received omeprazole capsule twice daily before meals and the rest of the drugs twice daily after meals for 14 days.
Study: NCT00384540

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dobutamine stress echocardiography, coronarography, brachial arterial echography
Description: DSE: cumulative doses of dobutamine (max = 40 µg/kg/min) and atropine (max = 1.5 mg), to reach a maximal heart rate under clinical, electrocardiographic and echocardiographic surveillancesCoronarography: invasive injection into coronary arteries of a radiological product showing a contrast visible on an x-ray. FMD: Flow-mediated dilatation of the brachial artery induced by 5-min forearm arterial occlusion
Study: NCT00089843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Testosterone patch 150mcg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Testosterone patch 150mcg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actonel (risedronate)
Description: Actonel (risedronate) 35mg PO one time weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actonel (risedronate)
Description: Actonel (risedronate) 35mg PO one time weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Actonel (risedronate)
Description: Placebo tablet identical in appearance to active Actonel (risedronate) tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Actonel (risedronate)
Description: Placebo tablet identical in appearance to active Actonel (risedronate) tablet
Study: NCT04576455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: Giredestrant is taken orally once per day on Days 1-28 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant or an Aromatase Inhibitor (Physician Choice)
Description: Physician choice of endocrine monotherapy (fulvestrant or an aromatase inhibitor) is taken in accordance with the local prescribing information for the respective product.
Study: NCT00089843

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo testosterone
Description: Placebo patch identical in appearance to testosterone patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo testosterone
Description: Placebo patch identical in appearance to testosterone patch
Study: NCT02674997

Intervention type: BIOLOGICAL
Intervention: Factor VIII
Description: Licensed Factor VIII products. Study is brand agnostic
Study: NCT01543490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-305
Description: Dexamethasone in DuraSite® 2 twice daily for 2 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle twice daily for 2 weeks